Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Durvalumab-Based Combination Therapy in Non–Muscle Invasive Bladder Cancer

By: Vanessa A. Carter, BS
Posted: Friday, February 5, 2021

Noah M. Hahn, MD, of Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, and colleagues conducted the ADAPT-BLADDER trial to determine the efficacy and safety of combining the immunotherapy durvalumab with BCR or radiation therapy in patients who have Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle invasive bladder cancer. Presented at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO; Abstract 22), their findings suggest the combination therapy is safe, with “promising” complete response rates in this patient population.

This phase I, multistage study enrolled 28 patients with BCG-unresponsive non–muscle invasive bladder cancer. Patients were administered durvalumab alone, durvalumab plus BCG therapy, or durvalumab plus external-beam radiotherapy (EBRT). Durvalumab was administered intravenously at 1,200 mg on day 1 of each 3-week cycle for at most 8 cycles. Every week for 6 weeks, 50 mg of BCG therapy was given intravenously with maintenance therapy for selected individuals. Those patients given EBRT received three separate 6-Gy fractions on days 1, 3, and 5 of the first cycle alone.

Participants' median age was 74, with 82% male; 15 patients had carcinoma in situ, 9 had high-grade Ta/T1 disease, and 4 had high-grade Ta/T1 plus carcinoma in situ. The median number of prior BCG regimens was two. Grade 3 to 4 treatment-related events such as hyperglycemia, elevated transaminase levels, rash, and elevated lipase levels affected one patient.

In one patient given durvalumab and EBRT, dose-limiting toxicity occurred, leading to a recommended phase II dose of 1,120 mg of durvalumab intravenously every 21 days combined with 50 mg of BCG therapy weekly or three 6-Gy fractions of EBRT. Complete response rates at 3 and 6 months for durvalumab alone, durvalumab plus BCG therapy, and durvalumab plus EBRT were 33% and 0%, 83% and 71%, and 55% and 33%, respectively. Translational biomarker analyses are yet to be presented.

Disclosure: For full disclosures of the study authors, visit suo-abstracts.secure-platform.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.